Sea-Tac expands global reach with nonstop flight to Rome
A slew of new nonstop routes around the world, including one to Rome, is turning SEA into a true global gateway.
Why it matters: Seattle is quickly shedding its status as a secondary international hub with the Seattle-Tacoma International Airport positioning itself as a serious player in the global aviation network.
Plus: Seattleites love to travel!
Driving the news: Alaska Airlines announced plans this week to launch nonstop service from Seattle to Rome — the first direct flight between the Emerald City and the Eternal City and the airline's first transatlantic route.
The route will begin in May 2026 and operate four times a week aboard Boeing 787-9 Dreamliners.
Rome is among the most-requested European destinations by Alaska Mileage Plan members, according to the Seattle-based carrier. It is also the largest in Europe without nonstop service from Seattle.
Also, Edelweiss Air began nonstop service to Zurich on Monday, and SAS started nonstop service to Copenhagen last month.
Zoom in: Alaska CEO Ben Minicucci, the son of Italian immigrants, called the Rome route "a dream come true."
"Our guests have been asking for an easy way to get to Italy for years," he said in a written statement.
The big picture: Sea-Tac has added new international service over the past two years, including flights to Taipei, Beijing and Chongqing, Munich, Manila, Liberia, Costa Rica, Toronto, and Tokyo, per the airport.
By the numbers: As of this month, Sea-Tac is offering nonstop flights to 36 international destinations, according to spokesperson Perry Cooper of the Port of Seattle.
That's up from 26 destinations in 2019.
Between the lines: The Rome announcement marks the third new intercontinental destination unveiled by Alaska in the last year.
The move is part of a broader expansion strategy following the Seattle-based carrier's acquisition of Hawaiian Airlines' wide-body aircraft, per Alaska.
Other European destinations being considered by Alaska include London, Paris, and Berlin.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Miami Herald
30 minutes ago
- Miami Herald
Popular HomeGoods rival shuttering dozens of locations
Retail businesses are shutting down at a rate so alarmingly fast in 2025, you may feel like you could blink and realize another has vanished. Perhaps the saddest story of a brand that called it quits in 2025 so far is Joann, a craft and fabric store beloved by its loyal customers. Joann was founded in 1943, so after 82 years of business, it was a shame to watch it close its doors. Don't miss the move: Subscribe to TheStreet's free daily newsletter Another chain that was incredibly strange to see go was Party City. After 40 years in business, the retailer announced in December 2024 that it would file for bankruptcy and cease operations. Related: Major retailer scores huge benefit from Joann bankruptcy At Home is the most recent major retail chain to file for bankruptcy, announcing it would close 26 underperforming stores by September 30. However, the business hasn't winked out of existence yet, as it's just entered into a Restructuring Support Agreement (RSA) with lenders holding more than 95% of its debt to eliminate the nearly $2 billion in funded debt and provide financing of $200 million that aims to support the retailer through its restructuring process. Now another longtime home goods store is making drastic moves to keep itself afloat in a challenging economic climate. Kirkland's (KIRK) , a Tennessee-based home good retailer that was founded in 1966 by Carl Kirkland and Robert Kirkland, has announced it will close at least two dozen of its 313 store locations. Kirkland's has not yet confirmed which locations will close. TheStreet has reached out to request more information. The closings are part of a rebranding process Kirkland's confirmed on June 17, where the company says it will change its name to The Brand House Collective. This move comes after Beyond Inc., parent company of both Bed, Bath & Beyond and Overstock, acquired Kirkland's IP in a $5 million acquisition. Related: IKEA suddenly closing more stores amid concerning customer trend While store closings typically sound like a bad thing, in this case they seem to be more of a strategic move in step with the company's other brands. Beyond plans to open the first of six Bed, Bath & Beyond Home stores in August 2025, with the first being in Brentwood, Tennessee. Some existing Kirkland stores will also be converted into Bed, Bath & Beyond Home stores, although the specific locations were not named. Kirkland's name will formally change after shareholder approval during its next annual meeting in July, which will also change its ticker from KIRK to TBHC. As consumers navigate an uncertain climate with the threat of tariffs looming, many have pulled back on nonessential purchases this year across many sectors, from food to clothing. Retail sales fell sharply in May, with sales at retail stores and restaurants dropping 0.9%, the Commerce Department reported. However, a few retailers are still seeing shoppers come their way. One is discount home retailer HomeGoods, which reported during its Q1 earnings call in May that comparable sales were up 4% year over year. "Bucking a trend in the home industry now is our home business, especially HomeGoods. We're quite proud the way they're beginning Q2 as well," TJX CEO Ernie Herrman told investors during the call. Related: Beloved local Mexican chain closes locations without warning The Arena Media Brands, LLC THESTREET is a registered trademark of TheStreet, Inc.
Yahoo
an hour ago
- Yahoo
Perspective Therapeutics Commences Recruitment for [212Pb]VMT-α-NET in the Third Dose Escalation Cohort of its Ongoing Phase 1/2a Clinical Trial
[212Pb]VMT-α-NET Phase 1/2a study is advancing into Cohort 3 with a fixed administered dose that is up to 20% higher (6 mCi) than the dose administered to patients in Cohort 2 Dosimetry sub-study analysis presented at the Society of Nuclear Medicine & Molecular Imaging (SNMMI) 2025 Annual Meeting to advance utility of dosimetry in clinical development when considered with clinical data On track to submit further clinical updates to scientific congresses in 2H 2025, including longer safety follow-up on all patients who have received at least one treatment of [212Pb]VMT-α-NET and anti-tumor activities in patients dosed to date who have had the opportunity to receive at least one scan after their full treatment SEATTLE, June 21, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced that alignment was reached with the U.S. Food and Drug Administration (FDA) to open the third dosing cohort (Cohort 3) of its ongoing Phase 1/2a clinical trial for [212Pb]VMT-α-NET in patients with unresectable or metastatic somatostatin receptor 2 (SSTR2)-positive neuroendocrine tumors (NETs) who have not received prior radiopharmaceutical therapies (RPT). "We are excited to start exploring a higher dose level of VMT-α-NET after successfully completing an interaction with the FDA that was agreed prior to commencement of this trial," commented Markus Puhlmann, Chief Medical Officer of Perspective. "We are encouraged by the overall clinical profile observed at the second dose level of VMT-α-NET—including evidence of anti-tumor activity and primarily low-grade adverse events—and we believe it is important to assess whether a higher dose could further improve the therapeutic profile. Meanwhile, we remain committed to engaging with the FDA to evaluate the clinical utility of dosimetry estimates and analyses in the development of our proprietary RPTs." Patients in Cohort 3 will receive up to four fixed administered doses of [212Pb]VMT-α-NET at 6 mCi every eight weeks if they weigh more than 60kg (133lb), or 100μCi/kg of body weight if they weigh less than or equal to 60kg. Observations of dose limiting toxicities (DLTs) in up to eight patients within 42 days of the first treatment cycle will be used to assess whether this cohort of patients have received maximum tolerated dose (MTD) or maximum feasible dose (MFD). Once a safety monitoring committee (SMC) has reviewed the data from these initial patients, it may recommend exploring alternative dosing and/or recruit more patients into Cohort 3. Perspective is notifying sites that Cohort 3 is now open for recruitment. Patients currently being evaluated for entry into the study will enroll into Cohort 3 if they qualify. Pending feedback from sites on operationalizing enrollment into Cohort 3, an update on pace of recruitment will be provided in due course. About [212Pb]VMT-α-NETPerspective designed [212Pb]VMT-α-NET to target and deliver 212Pb to tumor sites expressing SSTR2. The Company is conducting a multi-center, open-label, dose-escalation, dose-expansion study ( identifier NCT05636618) of [212Pb]VMT-α-NET in patients with unresectable or metastatic SSTR2-positive neuroendocrine tumors who have not received a prior RPT. Interim update with a data cut-off date of April 30, 2025 were reported in an oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in May 2025. Cohort 2 was reopened in August 2024. During 2H 2025, some of the 33 additional patients enrolled after the cohort reopened and through April 30, 2025 will have had the opportunity for at least 32 weeks of follow-up after their initial doses, sufficient time to receive at least one scan after their full treatment (up to four doses every eight weeks), if they receive all four doses of treatment per protocol. About Perspective Therapeutics, Therapeutics, Inc. is a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. The Company is also developing complementary imaging diagnostics that incorporate the same targeting moieties, which provides the opportunity to personalize treatment and optimize patient outcomes. This "theranostic" approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity. The Company's melanoma (VMT01), neuroendocrine tumor (VMT-α-NET), and solid tumor (PSV359) programs are in Phase 1/2a imaging and therapy trials in the U.S. The Company is growing its regional network of drug product finishing facilities, enabled by its proprietary 212Pb generator, to deliver patient-ready products for clinical trials and commercial operations. For more information, please visit the Company's website at Safe Harbor StatementThis press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include statements concerning, among other things, the Company's ability to pioneer advanced treatments for cancers throughout the body; the Company's belief that it is on track to submit further clinical updates to scientific congresses in 2H 2025 and the planned content of such updates; the Company's ability to explore a higher dose level of VMT-α-NET; the Company's commitment to engage with the FDA to evaluate the clinical utility of dosimetry estimates and analyses in the development of its proprietary RPTs; the Company's expectation that patients currently being evaluated for entry into its VMT-α-NET study will enroll into Cohort 3 if they qualify; the ability of the Company's proprietary technology utilizing the alpha emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties; the Company's prediction that the use of complementary imaging diagnostics that incorporate the same targeting moieties provides the opportunity to personalize treatment and optimize patient outcomes; the Company's belief that its "theranostic" approach enables the ability to see a specific tumor and then treat it to potentially improve efficacy and minimize toxicity; the Company's ability to grow its regional network of drug product finishing facilities, enabled by its proprietary 212Pb generator, to deliver patient-ready products for clinical trials and commercial operations; and other statements that are not historical fact. These forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from the results described in or implied by the forward-looking statements. Certain factors that may cause the Company's actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are described under the heading "Risk Factors" in the Company's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC"), in the Company's other filings with the SEC, and in the Company's future reports to be filed with the SEC and available at Forward-looking statements contained in this news release are made as of this date. Unless required to do so by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Media and Investor Relations Contacts: Perspective Therapeutics IR:Annie J. Cheng, CFAir@ Russo Partners, LLCNic JohnsonPerspectiveIR@
Yahoo
3 hours ago
- Yahoo
Red Sox address ‘unsubstantiated report' about using AI for baseball ops interviews
SEATTLE — The Red Sox on Wednesday released a statement to address an 'unsubstantiated report' that the organization uses AI to interview candidates for their baseball operations openings. Joon Lee made the claim on NBC Sports Boston's Arbella Early Edition on Tuesday, saying, 'The Red Sox were trying to recruit a new person for their baseball operations department, and during this interview process, the entire interview was conducted with an AI bot, where you would record the answers to the questions and then the Red Sox would then evaluate them. And this wasn't just one round. It wasn't just two rounds. It was five rounds of interviews where this person did not talk to another person in the Red Sox organization.' Advertisement The Red Sox released the following statement: 'We wanted to reach out to you because we are seeing unsubstantiated reports about the Red Sox using AI bots to hire candidates. ... Since 2012, the club has used a tool called HireVue to screen applicants for all roles across the organization. The Red Sox are one of several MLB clubs to use this tool, which asks candidates to answer a few questions in a recorded video for the hiring manager to get a sense of the person beyond their resume. This is one of several steps in the hiring process and is just one factor that helps determine which candidates should advance to an in-person interview. On average, the club receives over 500 applicants per position, and for some roles, as many as 3,000. This tool is in no way a replacement for in-person interviews, simply one of many steps that helps the club screen the many candidates who apply for each job posting. 'We wanted to ensure all of you had this information directly from us and would appreciate your partnership in helping clear up these unsupported claims.' More Red Sox coverage Read the original article on MassLive.
